Our study highlights the therapeutic potential of targeting GSPT1 protein, particularly in pediatric AML subtypes characterized by RUNX1::RUNX1T1 and FUS::ERG fusion genes. The gene discussed is GSPT1; the disease is acute myeloid leukemia.